Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies
CAR-neg T cells exhibit a significantly greater expansion compared to CAR-pos T cells alongside CAR-T cell production. The percentage of CAR-neg cells influences the specific cytotoxicity of the product and on the cytokine pattern, which might influence both efficacy and toxicity and, therefore, the number of CAR-neg T cells within the infusion product must be considered in the clinical setting. Purification of CAR-pos T cells could potentially optimize product characteristics.
Authors
- Belén Sierro-Martínez
- Francisco Garcı́a-Cózar (ORCID: https://orcid.org/0000-0003-3720-259X)
- Maribel Lara‐Chica (ORCID: https://orcid.org/0000-0003-2908-9929)
- Virginia Escamilla Gómez (ORCID: https://orcid.org/0000-0002-0639-574X)
- Estefanía García‐Guerrero (ORCID: https://orcid.org/0000-0002-3041-9860)
- Raquel Muñoz-García
- Beatriz Guijarro-Albaladejo (ORCID: https://orcid.org/0000-0001-5848-3875)
- Alfonso Rodríguez‐Gil (ORCID: https://orcid.org/0000-0003-4430-077X)
- Inmaculada Carrasco-Brocal
- Paola Hernández-Díaz
- Josè Antonio Pérez-Simón (ORCID: https://orcid.org/0000-0003-3616-6101)
- Ricardo Fernández-Cisnal (ORCID: https://orcid.org/0000-0001-5307-8539)
- María de la Rosa-Garrido
- Ángela Bella
Institutions
- Biomedical Research and Innovation Institute of Cadiz (ES)
- Instituto de Biomedicina de Sevilla (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Universidad de Sevilla (ES)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-08-19
- DOI
- https://doi.org/10.1186/s12967-025-06899-0
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- European Commission
- Ministerio de Ciencia e Innovación
- Junta de Andalucía
- Instituto de Salud Carlos III